Welcome to our dedicated page for Axcella Health news (Ticker: AXLA), a resource for investors and traders seeking the latest updates and insights on Axcella Health stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Axcella Health's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Axcella Health's position in the market.
Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company, announced two poster presentations at The Liver Meeting® 2020, set for November 13-16, 2020. The presentations will showcase findings from the AXA1125-003 clinical study, focusing on subjects with type 2 diabetes and the overall study population.
Key abstracts include:
- 1663: Examining biological activity related to glucose and liver fat in NAFLD patients with type 2 diabetes.
- 1694: Safety and biological activity of AXA1125 and AXA1957 in NAFLD patients.
Axcella (Nasdaq: AXLA), a biotechnology company, announced a publication in iScience highlighting the potential of endogenous metabolic modulator (EMM) compositions to treat complex diseases. The publication discusses how EMMs like amino acids can address multiple biological pathways, providing safe, multifactorial treatments. Axcella's research indicates positive outcomes from five clinical studies targeting conditions like non-alcoholic steatohepatitis (NASH) and overt hepatic encephalopathy (OHE). The company aims to further advance its candidates into later-stage clinical trials.
Axcella (Nasdaq: AXLA) announced participation in a fireside chat at the H.C. Wainwright 4th Annual NASH Investor Conference on October 5, 2020, at 1:30 p.m. ET. The discussion will be streamed live on the company’s website, with a replay available for 30 days post-event. Axcella is focusing on developing innovative treatments using endogenous metabolic modulator compositions for complex diseases, particularly targeting non-alcoholic steatohepatitis (NASH) and reducing the risk of overt hepatic encephalopathy recurrence. For more details, visit www.axcellahealth.com.